SCHEMBL506663

SCHEMBL506663

Oc1cccc2c1CC=CC2

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BCL2L1 Q07817 1/20 0.50
BAD Q92934 1/20 0.50
DRD2 P14416 2/20 0.41
DRD3 P35462 2/20 0.41
DRD1 P21728 1/20 0.39
DRD5 P21918 1/20 0.39
ALDH1A1 P00352 2/20 0.39
ALOX15 P16050 2/20 0.39
HSD17B10 Q99714 2/20 0.39
TDP1 Q9NUW8 2/20 0.39
MEN1 O00255 1/20 0.39
USP2 O75604 1/20 0.39
HPN P05981 1/20 0.39
CYP3A4 P08684 1/20 0.39
ALOX5 P09917 1/20 0.39
MAPT P10636 1/20 0.39
THRB P10828 1/20 0.39
TSHR P16473 1/20 0.39
PTGS1 P23219 1/20 0.39
PDE4A P27815 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2150662 0.94 BCL2L1 (0.45) BCL2L1BADDRD2DRD3DRD1
Acetic Acid SCHEMBL11352341 0.88 BCL2L1 (0.41) BCL2L1BADDRD2DRD3DRD1
Isopropylamine SCHEMBL11669368 0.88 BCL2L1 (0.41) BCL2L1BADDRD2DRD3DRD1
SCHEMBL3962200 0.81 BCL2L1 (0.50) BCL2L1BADDRD2DRD3DRD1
SCHEMBL8676261 0.73 PIM1 (0.35) BCL2L1BADALDH1A1ALOX15HSD17B10
SCHEMBL16772449 0.73 AURKA (0.33) ALDH1A1ALOX15HSD17B10TDP1MEN1
SCHEMBL21092188 0.71 DRD2 (0.33) DRD2DRD1ALDH1A1ALOX15HSD17B10
SCHEMBL11788924 0.71 CYP1A2 (0.36) BCL2L1BADALDH1A1TSHRCA1
SCHEMBL8527304 0.71 CD44 (0.44) ALDH1A1ALOX15HSD17B10TDP1MEN1
SCHEMBL19011783 0.71

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 123 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2013083582-A1 ANTIMICROBIAL COMPOSITION UNILEVER N.V. (NL) 2013-06-13 WO claimed
JP-3081238-A None JP disclosed
EP-3838900-B1 3-ARYLOXY-3-ARYL-PROPYLAMINE COMPOUND AND USES THEREOF ZHANGZHOU PIEN TZE HUANG PHARM (CN) 2025-02-12 EP disclosed
US-20250019593-A1 RENEWABLE DIESEL PRODUCTION FROM CATALYTIC PYROLYSIS FEEDSTOCK IFP Energies Nouvelles (FR) 2025-01-16 US disclosed
US-20250011655-A1 RENEWABLE JET PRODUCTION FROM CATALYTIC PYROLYSIS FEEDSTOCK IFP Energies Nouvelles (FR) 2025-01-09 US disclosed
US-20240336588-A1 COMPOSITIONS AND METHODS FOR ANTIOXIDANT AND ANTI-INFLAMMATORY THERAPEUTICS AVANTI BIOSCIENCES, INC. 2024-10-10 US disclosed
EP-4433552-A1 RENEWABLE DIESEL PRODUCTION FROM CATALYTIC PYROLYSIS FEEDSTOCK IFP Energies nouvelles (FR) 2024-09-25 EP disclosed
EP-4433553-A1 RENEWABLE JET PRODUCTION FROM CATALYTIC PYROLYSIS FEEDSTOCK IFP Energies nouvelles (FR) 2024-09-25 EP disclosed
CN-115611708-B Preparation method of rotigotine impurity K 北京福元医药股份有限公司沧州分公司 2024-08-06 CN disclosed
CN-118302504-A Preparation of renewable jet fuel from catalytic pyrolysis feedstock IFP 新能源公司 2024-07-05 CN disclosed
US-4265911-A Propionamidoxime derivatives SYNTHELABO (FR) 1981-05-05 US disclosed
US-4156789-A INTERMEDIATES, ANTIFIBRILLATORY AGENTS E. R. SQUIBB & SONS, INC. (US) 1979-05-29 US disclosed
US-4082773-A TRICYCLIC TETRAHYDRO NAPHTHALENEOLS AND RELATED COMPOUNDS E. R. SQUIBB & SONS, INC. (US) 1978-04-04 US disclosed
US-4029676-A ANTIADRENERGIC, ANTIFIBRILLATORY E. R. SQUIBB & SONS, INC. (US) 1977-06-14 US disclosed
US-4003930-A 2,3-Trans-5-[3-(amino)-2-hydroxy-propoxy]-1,2,3,4-tetrahydro-3-(or 2)-amino-2-(or 3)-hydroxy-naphthalenes and salts thereof E. R. SQUIBB & SONS, INC. (US) 1977-01-18 US disclosed
US-3982021-A Compositions for the treatment of coronary diseases containing tetrahydronaphthyloxy-aminopropanols E. R. SQUIBB & SONS, INC. (US) 1976-09-21 US disclosed
US-3969392-A PARASITICIDE, BACTERICIDE, ANTIINFLAMMATORY, SURFACTANT E. R. SQUIBB & SONS, INC. (US) 1976-07-13 US disclosed
US-3956285-A CORONARY DISEASES, WATER SOFTENERS, CORROSION INHIBITORS E. R. SQUIBB & SONS, INC. (US) 1976-05-11 US disclosed
US-3943149-A HYPOCHOLESTEREMIC, ANTIINFLAMMATORY E. R. SQUIBB & SONS, INC. (US) 1976-03-09 US disclosed
US-3935267-A CARDIOVASCULAR DISORDERS E. R. SQUIBB & SONS, INC. (US) 1976-01-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240336588-A1 COMPOSITIONS AND METHODS FOR ANTIOXIDANT AND ANTI-INFLAMMATORY THERAPEUTICS MPO, GPX4, GPX1 BCL2L1 676/4885BAD 1575/4885DRD2 3074/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.